Ivelina Velikova manages projects involving the analysis of economic issues in securities litigation matters. She has consulted on hundreds of securities class actions, including examining materiality, loss causation, and liability and estimating inflation, damages, and settlements. Ms. Velikova has extensive knowledge of the FDA drug approval process and the pharmaceutical and biotech industries. Her expertise also includes closed-end funds, banking, asset management, insurance and reinsurance, oil and gas, broadband networking, and mortgage servicing across geographies including the US, Canada, China, France, and Puerto Rico.
Ms. Velikova has consulted on numerous matters involving disputes between brokerage firms and their customers concerning investments in equity, fixed-income securities, and funds. She has evaluated the concentration and use of leverage of investment portfolios and municipal closed-end funds; the performance and characteristics of municipal bonds, municipal closed-end funds, and municipal markets; and damages and investment suitability. She has also assessed market efficiency and assisted with class certification analyses. Her experience includes cases involving accounting restatements, FDA decisions, and public offerings (Section 11 and 12 claims and mergers and acquisitions). In other matters, Ms. Velikova has consulted on failed bank litigation, ERISA suits, SEC actions, and derivative litigation. She has calculated damages resulting from breaches of contract and alleged ill-gotten gains from insider trading. Ms. Velikova also assists insurance brokers with analyses of litigation exposure under hypothetical scenarios in the context of D&O insurance coverage decisions.